Fast & reliable oral cancer detection
In the last years 2M coordinated two European projects around early cancer detection. 2M build up extensive knowhow and expertise on fluorescence imaging techniques for detection of oral cancer.
Reliable recognition of cancerous cells
The first project was a fundamental research project to create the technological and medical essential building blocks to discriminate cancerous cells from non-cancerous cells. The second project was a so-called demonstrator project focused on oral cancer detection. Two prototypes are available as a result of these projects. Both technically feasible and with a direct interest from the involved medical specialists.
- Fewer biopsies – improved interpretation of oral mucosal abnormalities leading to fewer referrals/biopsies.
- Real-time imaging during surgery
- Identify lesion type – Cross references to lesion database to help identify the lesion type.
- Superior differential diagnosis
- Indicates optimum biopsy sites
- Superior sensitivity and specificity
- Patented technologies
- Despite the general accessibility of the oral cavity, multiple screening and detection techniques during physical examination, many malignancies are not diagnosed until late stages of disease.
- Occurrence of oral cancer in 2012 resulted in 372,000 new cases and over 150,000 deaths. 5 year mortality is approx. 50%. 8th most common cancer for men; Often no visible lesions or discolorations in early stage (local). Risk factors: tobacco, alcohol and HPV 16. Sufferers are 20 times higher risk of developing a second cancer. Early diagnosis results in >80% survival.
- Total market is 12,500 practices, total value of market is > 150 M€/yr.
- Primary screeners include: Otolaryngologists, Oral Maxillofacial Surgeons, Dentists, Radiation Oncologists, and Nurse Practitioners. Test: History, COE, Adjunctive tools (Blue light, Dye, Brush Biopsy). Result: Referral or Biopsy. No Diagnosis is made.
Specifications of the EDOCAL system
- Setup for multi-wavelength tissue illumination and integrade sensing
- Technology: multi-wavelength fluorescence imaging
- Application: mouth and throat cancer
- Clinical trial completed
- Complete technical optical, hardware, signal processing & application development by 2M
- Wavelengths: 6 laser sources and 4 LEDs from 365nm to 625nm
- Spectrometer based signal processing
- Light directed via optical fiber to human tissue
- Fluorescence “return” emission collected via same fiber
- Light information is analyzed with computer with signal processing software
Combining fluorescence & conventional imaging techniques
Improved fluorescence using multi-wavelength laser technology
Technological solution based on the combination of a multi-laser sensor, image reference database and analytical software/algorithms. This solution provides effective diagnostic indications of tissue under investigation.
Conventional camera based imaging
An oral imaging system that helps to visualize and track progress of certain problems over time and provides fact based information about the problem area. The solution is affordable and can easily be added to any dentist practice.
System integrator, miniaturization and application
2M supports all development steps from early research to functional prototypes to final product.
First functional model
Focus: narrow band light sources, enough output power, clarify exact requirements with clinicians.
Fully portable device for clinical tests
Miniaturization, downsizing, cost-down engineering, clinical use and approval requirements.
Practical side tools for mouth and throat cancer
Patient management software application
Spot & log progression of ulcers over time
Image morphing to allow easy comparison between images
Stores all edocal measurement data providing single interface
Earlier H2020 projects on cancer detection using laser photonics
The project is funded under the FP7 program. Project name: EDOCALD (FP7 project number 605254)
In cancer, tissue cells tend to create many additional blood vessels to support their growth. The molecule protoporphyrin (PpIX) is generally present in blood vessels and exhibits red fluorescence when excited with UV or blue light in the 360-425 nm range. Cancer cells and pre-cancer cells are detected by observing the red fluorescence at a matching excitation wavelength. The wavelength of the laser has to be tunable as the matching wavelength depends on the person, type of illness and presence of other chemicals. Baselines are created using surrounding healthy tissue.
Advanced Bladder cancer LAser Diagnostics and thErapy (ABLADE)
Seventh Framework Programme, Grant Agreement No: 324370
Project Start Date: 10/04/2013
The ABLADE project stems from the innovative idea to transfer the technologies of multi-functional lasers to the endoluminal approach for managing the diagnosis and treatment of urinary bladder cancers, thus improving early diagnosis and accuracy over the current white light based endoscopic approach and transurethral resection using electrodiathermy.
This transfer of knowledge is enabled by the incorporation of new laser sources with different wavelengths into a compact system designed specifically to address some of the unmet clinical needs identified by a large systematic review with meta analysis and cost-effectiveness study.
The ultimate goal of ABLADE is to dramatically enhance the advantages of traditional flexible endoscopic inspection of the urinary bladder by integrating new multifunctional laser diagnostic and phototherapy technologies to realise a system suitable for outpatients or day case based diagnosis and treatment of the urinary bladder.
Early Cancer Detection Using Photonic Crystal Lasers (EDOCAL)
The EDOCAL project is being funded by the 7 th Framework Program for Research and Technological Development, grant agreement number 231993, by the European Union.
The aim of the EDOCAL project is to create a breakthrough tool for early detection of cancerous cells by combining state of the art laser and imaging technology with leading medical research. It combines advanced, proven, low cost telecom and state of the art semiconductor technologies with the latest advances and insights into medical procedures provided by the RTD partners.